Meaningful Use Consulting

Are you required to attest for Meaningful Use Stage 2? Yes, you are.

The updated timeline for Meaningful Use participation is outlined below. Notice that beginning in 2016*, all providers, regardless of past participation, must attest to the modified Stage 2 requirements or face a penalty.

Modified Stage 2 Requirements

  1. Confirm your EHR is certified to the 2014 Edition standards
  2. Understand the modifications for 2015–2017. Attest to:
    • Nine objectives which require that you:
      • Implement a patient portal
      • Ensure lab and imaging interfaces are in place
      • Set up your Direct address
      • Connect to an HIE for transitions of care
      • Complete security risk analysis
    • Two public health registries, from these options:
      • Immunization
      • Syndromic surveillance
      • Specialized registry
      • Cancer registry
    • Nine clinical quality measures

Contact Miraca Life Sciences to learn how Miraca can assist your practice.
Call 1.855.347.7284 or email EHRPath@MiracaLS.com

The support team at Miraca has been invaluable in helping us with Meaningful Use. They are beyond experts in their field, and have saved us countless hours.
— Michael H. Coverman, MD,
Austin Dermatology Clinic, PA, Austin, Texas


READ MORE
Learn about Miraca's unmatched quality. We provide our clients with access to the highest quality AP services.

Recent News


March 27, 2017

Simponi® is Sixth Drug in InformTx™ Therapeutic Drug Monitoring Service from Miraca Life Sciences

IRVING, Texas, March 28, 2017 — Miraca Life Sciences, the largest U.S. independent anatomic pathology laboratory, continues to expand its InformTx™ therapeutic drug monitoring (TDM) capabilities, now testing for Simponi (golimumab) as well as patient-developed antibodies to Simponi. This is the first TDM assay available in the United States for Simponi. With this addition, Miraca Life Sciences now performs TDM […]

Continue reading


November 30, 2016

Stelara® Now Available for Therapeutic Drug Monitoring from Miraca Life Sciences

IRVING, Texas, December 1, 2016 — Miraca Life Sciences, the largest U.S. independent anatomic pathology lab, has expanded its InformTx™ therapeutic drug monitoring service for drugs that treat inflammatory bowel disease (IBD) with the addition of Stelara (ustekinumab).

Miraca Life Sciences continues to perform therapeutic drug monitoring (TDM) for Remicade® (infliximab), Humira® (adalimumab), Cimzia® (Certolizumab pegol) and Entyvio® (vedolizumab). Since […]

Continue reading


August 10, 2016

Ten Research Projects from Miraca Life Sciences Accepted for ACG Conference

IRVING, Texas, August 10, 2016 — Ten research projects from the GI pathologists at Miraca Life Sciences, the nation’s largest independent anatomic pathology lab, have been accepted for presentation at the Annual Meeting of the American College of Gastroenterology (ACG), which will be held October 14–19 in Las Vegas.

Authors from Miraca Life Sciences are linked below to their profile […]

Continue reading


July 13, 2016

Miraca Life Sciences Launches Easy Way to Complete GIQuIC Pathology Section

IRVING, Texas, July 13, 2016 — Working with a leading vendor of gastroenterology software, Miraca Life Sciences, the nation’s largest independent anatomic pathology lab, now enables the pathology section of the GIQuIC form to populate automatically. Miraca Life Sciences’ structured diagnosis data and smart electronic interfaces facilitate this easier process, which improves the current approach of using free-form text for […]

Continue reading


Miraca Life Sciences Adds New Way to Complete GIQuIC Pathology Section and Automate ADR Tracking

IRVING, Texas, July 13, 2016 — Miraca Life Sciences, the nation’s largest independent anatomic pathology lab, has worked closely with Wolters Kluwer throughout its latest software release of ProVation® MD to automatically populate the pathology section of the GIQuIC form for single colonoscopies, which will save hours of time for clients. Miraca Life Sciences’ use of structured diagnostic terminology combined […]

Continue reading